Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

NCT01677390 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01677390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01677390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2012
Completion date
December 31, 2013
Enrollment
4 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma